Tuesday, October 19, 2021


Quantum-Si Publicizes Growth of Early Entry Program for the Platinum™ Single Molecule Protein Sequencing Platform

GUILFORD, Conn.–(BUSINESS WIRE)–Quantum-Si Included (NASDAQ: QSI) (“Quantum-Si,” “QSI” or the “Firm”), a life science instruments firm commercializing a singular protein…

By Staff , in Platinum , at October 19, 2021


GUILFORD, Conn.–(BUSINESS WIRE)–Quantum-Si Included (NASDAQ: QSI) (“Quantum-Si,” “QSI” or the “Firm”), a life science instruments firm commercializing a singular protein sequencing platform, introduced as we speak that they’ve expanded their Platinum early entry program to 10 websites, with participation from main educational facilities and key business companions. The early entry program introduces the Platinum single molecule sequencing system to key opinion leaders throughout the globe, for each enlargement and growth of functions and workflows.

“The Firm is experiencing large momentum and demand for participation in our early entry program to research beforehand unapproachable ranges of organic understanding of the proteome,” stated John Stark, Chief Government Officer of Quantum-Si. “At the moment, the scientific and drug growth group can solely affirm ~20,000 proteoforms or 2% of the estimated 1 million protein buildings or variants that will exist in a cell. Sequencing the proteome is poised to increase the general market much like how genomics empowered scientists to routinely sequence genes on the nucleic acid degree. That is solely the start for what will probably be enabled.”

QSI is accelerating the event of functions to handle vital unmet wants throughout key market segments together with basic organic discovery and analysis, medical and therapeutic biomarker growth, and broadening single molecule sequencing for multi-omic approaches. With Platinum’s scaled protein evaluation of single molecules at amino acid degree decision, early entry contributors will discover:

  • Multi-omic assay growth to increase organic understanding. “Inside a month of receiving the instrument, we had been in a position to reproduce and validate protein sequencing knowledge beforehand generated at Quantum-Si,” stated Dr. Andrew Griffiths, Professor on the Ecole Superieure de Physique et de Chimie Industrielles (ESPCI) in Paris. “We at the moment are utilizing the instrument to run our personal samples to develop single molecule screening for directed evolution, parallelized single molecule counting functions and single-cell multi-omics.”

    “Developments in life science applied sciences are required to allow a higher understanding of molecular adjustments that trigger illness, enabling higher decision of cell and basic protein construction,” stated Dr. Andrew Adey, Affiliate Professor at Oregon Well being & Science College. “My group is enthusiastic concerning the potential to sequence proteins to supply basic understanding in key areas resembling unlocking the complexity of neurologic operate and illness.”

  • Unlocking measurement of biomarkers which are difficult for traditional platforms to scale. “Instruments able to characterizing amino acid modifications like phosphorylation, the important mechanism by which cells ‘sign’ data in most cancers and just about each different illness, are important for growth of recent biomarkers that increase routine medical laboratory testing,” stated Dr. Timothy Triche, Co-Director for the Youngsters’s Hospital Los Angeles (CHLA) Heart for Personalised Drugs. “A key analysis focus of our group is to grasp how the Platinum platform can be utilized to essentially improve affected person monitoring for early detection and reoccurrence.”
  • Superior instruments to higher perceive complicated problems with the immune system. “Thousands and thousands of sufferers are experiencing the consequences of lengthy hauler signs or immunocompromised states which are difficult to diagnose at early phases,” stated Dr. Bruce Patterson, Chief Government Officer at inCellDX. “At our firm and related clinics, we’re observing viral protein signatures in these affected person samples during which nucleic acid materials is absent, confirmed by complete genome sequencing of viral load. Proper now, we’re exploring utilizing Platinum’s single molecule sensitivity to detect these low considerable protein signatures for early detection of lengthy hauler results.”

“Quantum-Si is creating easy end-to-end options and workflows that increase entry to single molecule protein sequencing for broad use throughout each fundamental and medical analysis markets,” stated Matt Dyer, Chief Enterprise Officer of Quantum-Si. “Our early entry program is a vital milestone in the direction of scaled commercialization. We’re excited to work intently with key thought leaders who share and increase our imaginative and prescient to advance the group’s understanding of the proteome and the way we in the end determine and deal with illness.”

About Quantum-Si Included

Based by Dr. Jonathan Rothberg in 2013, Quantum-Si is targeted on revolutionizing the rising discipline of proteomics. The Firm’s suite of applied sciences is powered by a first-of-its-kind semiconductor chip designed to allow single molecule next-generation protein sequencing and digitize proteomic analysis as a way to advance drug discovery and diagnostics past what has been attainable with DNA sequencing.

Ahead-Wanting Statements

This press launch consists of “forward-looking statements” inside the that means of the “protected harbor” provisions of america Non-public Securities Litigation Reform Act of 1995. The Firm’s precise outcomes might differ from its expectations, estimates, and projections and, consequently, you shouldn’t depend on these forward-looking statements as predictions of future occasions. Phrases resembling “anticipate,” “estimate,” “mission,” “price range,” “forecast,” “anticipate,” “intend,” “plan,” “might,” “will,” “might,” “ought to,” “believes,” “predicts,” “potential,” “proceed,” and related expressions (or the detrimental variations of such phrases or expressions) are meant to determine such forward-looking statements. These ahead wanting statements embrace, with out limitation, the Firm’s expectations with respect to future efficiency and growth of services; the advantages of the early entry program; the Firm’s plans to develop and commercialize Platinum and the Firm’s different strategic plans for its enterprise; the usage of the Firm’s expertise to increase life sciences markets, the understanding of molecular adjustments that trigger illness, and the event of recent biomarkers; and the demand for Platinum. These forward-looking statements contain vital dangers and uncertainties that might trigger the precise outcomes to vary materially from these mentioned within the forward-looking statements. Most of those components are outdoors the Firm’s management and are troublesome to foretell. Elements that will trigger such variations embrace, however aren’t restricted to: the impression of COVID-19 on the Firm’s enterprise; the shortcoming to keep up the itemizing of the Firm’s shares of Class A typical inventory on The Nasdaq Inventory Market; the power to acknowledge the anticipated advantages of the not too long ago accomplished enterprise mixture, which can be affected by, amongst different issues, competitors and the power of the Firm to develop and handle development profitably and retain its key workers; adjustments in relevant legal guidelines or laws; the power of the Firm to lift financing sooner or later; the success, value and timing of the Firm’s product growth actions; the potential attributes and advantages of the Firm’s services; the Firm’s capability to acquire and keep regulatory approval for its merchandise, and any associated restrictions and limitations of any accepted product; the Firm’s capability to determine, in-license or purchase extra expertise; the Firm’s capability to keep up its present lease, license, manufacture and provide agreements; the Firm’s capability to compete with different firms at the moment advertising or engaged within the growth of services that the Firm is creating; the dimensions and development potential of the markets for the Firm’s future services, and its capability to serve these markets, both alone or in partnership with others; the pricing of the Firm’s services following anticipated business launch; the Firm’s estimates concerning future bills, future income, capital necessities and wishes for added financing; the Firm’s monetary efficiency; and different dangers and uncertainties indicated occasionally within the Firm’s Quarterly Report on Kind 10-Q for the quarter ended June 30, 2021, together with these beneath “Threat Elements” therein, and within the Firm’s different filings with the SEC. The Firm cautions that the foregoing checklist of things isn’t unique. The Firm cautions readers to not place undue reliance upon any forward-looking statements, which communicate solely as of the date made. The Firm doesn’t undertake or settle for any obligation or enterprise to launch publicly any updates or revisions to any forward-looking statements to mirror any change in its expectations or any change in occasions, situations, or circumstances on which any such assertion relies.



Source link

Comments